Royalty Pharma (RPRX) Total Current Liabilities (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Total Current Liabilities data on file, last reported at $535.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 54.71% year-over-year to $535.7 million; the trailing twelve-month figure through Mar 2026 stood at $535.7 million (down 54.71% YoY), and the FY2025 full-year result was $636.2 million, down 49.25% from the prior year.
• Total Current Liabilities slipped to $535.7 million in Q1 2026, from $636.2 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $1.3 billion in Q4 2024 to a low of $124.6 million in Q1 2024.
• A 5-year average of $712.3 million and a median of $636.2 million in 2025 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities slumped 88.85% in 2024 and soared 849.52% in 2025, its largest moves.
• Tracing RPRX's Total Current Liabilities over 5 years: stood at $1.2 billion in 2022, then slumped by 86.17% to $161.4 million in 2023, then surged by 676.82% to $1.3 billion in 2024, then plunged by 49.25% to $636.2 million in 2025, then dropped by 15.8% to $535.7 million in 2026.
• Business Quant data shows RPRX's Total Current Liabilities at $535.7 million in Q1 2026, $636.2 million in Q4 2025, and $530.8 million in Q3 2025.